All In MedTech

Device Trial Radar · NCT05242276

Uterine Manipulator in Endometrial Cancer Surgery: Pro MUCEI Study

A Prospective Study of the Impact of Uterine Manipulator on Oncological Outcome in Endometrial Cancer Surgery in Early-stage: Pro MUCEI Study

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

1,200

Planned (sponsor's estimate)

Start

Mar 20, 2022

Primary completion

Mar 20, 2024

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Instituto de Investigacion Sanitaria La FeAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 16, 2022

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
Female only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The uterine manipulator is a device commonly used in minimally invasive hysterectomy surgery for endometrial cancer. However, without substantial evidence to support its use, surgeons are required to make decisions about its use based only on their personal choice and surgical experience. A retrospective study demonstrated how uterine manipulator use in early-stage endometrial cancer (FIGO I-II) for minimally invasive surgery was associated with a worse oncologic outcome in patients with uterus-confined endometrial cancer (FIGO I-II) who underwent minimally invasive surgery. The main objective of this study is to prospectively confirm the results obtained retrospectively, assessing the relapse rate in these patients related to the use or not of a uterine manipulator during the endometrial surgery. Secondary, the presence of risk factors that contraindicate the use of the uterine manipulator will also be evaluated.

Conditions

  • Endometrial Cancer

Interventions

  • USE OF UTERINE MANIPULATOR DURING THE HYSTERECTOMYDevice

    The uterine manipulator is a device commonly used in minimally invasive hysterectomy surgery for endometrial cancer. However, without substantial evidence to support its use, surgeons are required to make decisions about its use based only on their personal choice and surgical experience. . It is inserted vaginally through the cervical canal into the endometrial cavity. The uterine manipulator facilitates the uterus mobilization during the surgery, generating tension on the main supporting elements of the uterus to improve surgical field exposure and provide a landmark for the colpotomy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relapse rateTime frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital universitario y politécnico La Fe

    Valencia, Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.